Advertisement

Topics

Pfizer's Fragmin injection secures FDA approval in paediatric symptomatic venous thromboembolism

05:46 EDT 17 May 2019 | Pharmafile

The FDA has announced its approval of Pfizer’s anticoagulant injection Fragmin (dalteparin sodium) for subcutaneous use as a treatment to reduce the recurrence of symptomatic venous thromboembolism (VTE) in children at least one month of age.

Data submitted in support of the application was drawn from 38 paediatric participants with the condition; it was found that 21 patients achieved resolution of the qualifying VTE, while seven showed regression and two did not see their condition change.

read more

Original Article: Pfizer's Fragmin injection secures FDA approval in paediatric symptomatic venous thromboembolism

NEXT ARTICLE

More From BioPortfolio on "Pfizer's Fragmin injection secures FDA approval in paediatric symptomatic venous thromboembolism"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...